DDInter456 DDInter1676
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Cyclophosphamide {u} (Compound) resembles {v} (Compound) Mechlorethamine
Cyclophosphamide {u} (Compound) binds {v} (Gene) CYP3A4
Cyclophosphamide {u} (Compound) downregulates {v} (Gene) ENOPH1
Cyclophosphamide {u} (Compound) causes {v} (Side Effect) Impaired healing
Cyclophosphamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Cyclophosphamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Peginterferon alfa-2a
Cyclophosphamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mitomycin
Cyclophosphamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Cyclophosphamide {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Cyclophosphamide {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Cyclophosphamide (Compound) resembles Mechlorethamine (Compound)
Cyclophosphamide (Compound) binds CYP3A4 (Gene)
Cyclophosphamide (Compound) downregulates ENOPH1 (Gene)
Cyclophosphamide (Compound) causes Impaired healing (Side Effect)
Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Modafinil
Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Peginterferon alfa-2a
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Cyclophosphamide may lead to a major life threatening interaction when taken with Golimumab
Cyclophosphamide may lead to a major life threatening interaction when taken with Cladribine